12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Baraclude entecavir regulatory update

FDA updated the label for HBV drug Baraclude entecavir from Bristol-Myers to include data on African-Americans and liver transplant recipients...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >